{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:39Z","timestamp":1791632259163,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07469-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:27:30Z","timestamp":1764347250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systemic sclerosis: bridging clinical and molecular insights: results from the PRECISESADS study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-8529-0125","authenticated-orcid":false,"given":"Santiago","family":"Dans-Caballero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Ortega-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chary","family":"L\u00f3pez-Pedrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Escudero-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Vell\u00f3n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Precisesads Clinical Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clementina","family":"L\u00f3pez-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"7469_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(22)01692-0","volume":"401","author":"ER Volkmann","year":"2022","unstructured":"Volkmann ER, Andr\u00e9asson K, Smith V. Systemic sclerosis. Lancet. 2022, Nov, 25;401:304\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(22)01692-0.","journal-title":"Lancet"},{"issue":"3","key":"7469_CR2","doi-asserted-by":"publisher","first-page":"e001694","DOI":"10.1136\/rmdopen-2021-001694","volume":"7","author":"VK Bournia","year":"2021","unstructured":"Bournia VK, Fragoulis GE, Mitrou P, Mathioudakis K, Tsolakidis A, Tektonidou MG, et al. All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019. RMD Open. 2021, Nov;7(3):e001694. https:\/\/doi.org\/10.1136\/rmdopen-2021-001694.","journal-title":"RMD Open"},{"key":"7469_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226430","author":"F Del Galdo","year":"2024","unstructured":"Del Galdo F, Lescoat A, Conaghan PG, Bertoldo E, J \u010c, Santiago T, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2024, Oct. https:\/\/doi.org\/10.1136\/ard-2024-226430.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7469_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","volume":"51","author":"M Elhai","year":"2012","unstructured":"Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatol (Oxford). 2012, Jun;51(6):1017\u201326. https:\/\/doi.org\/10.1093\/rheumatology\/ker269.","journal-title":"Rheumatol (oxford)"},{"issue":"1","key":"7469_CR5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","volume":"21","author":"MR Pokeerbux","year":"2019","unstructured":"Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Launay D, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019, Apr, 3;21(1):86. https:\/\/doi.org\/10.1186\/s13075-019-1867-1.","journal-title":"Arthritis Res Ther"},{"key":"7469_CR6","doi-asserted-by":"publisher","first-page":"152604","DOI":"10.1016\/j.semarthrit.2024.152604","volume":"70","author":"L Cano-Garc\u00eda","year":"2025","unstructured":"Cano-Garc\u00eda L, Garc\u00eda-Studer A, Manrique-Arija S, Ortiz-M\u00e1rquez F, Redondo-Rodr\u00edguez R, Fern\u00e1ndez-Nebro A, et al. Accrual of organ damage and one-year mortality in systemic sclerosis: a prospective observational study. Semin Arthritis Rheum. 2025, Feb;70:152604. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152604.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"7469_CR7","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Ta M Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988, Feb;15(2):202\u201305.","journal-title":"J Rheumatol"},{"issue":"1","key":"7469_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5301\/jsrd.5000231","volume":"2","author":"D Khanna","year":"2017","unstructured":"Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017, Jan-Apr;2(1):11\u201318. https:\/\/doi.org\/10.5301\/jsrd.5000231.","journal-title":"J Scleroderma Relat Disord"},{"issue":"4","key":"7469_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nrrheum.2014.22","volume":"10","author":"J Varga","year":"2014","unstructured":"Varga J, Hinchcliff M. Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets? Nat Rev Rheumatol. 2014, Apr;10(4):200\u201302. https:\/\/doi.org\/10.1038\/nrrheum.2014.22.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"7469_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","volume":"45","author":"N Srivastava","year":"2015","unstructured":"Srivastava N, Hudson M, Tatibouet S, Wang M, Baron M, Fritzler MJ; Canadian Scleroderma Research Group (CSRG). Thinking outside the box\u2013the associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Semin Arthritis Rheum. 2015, Oct;45(2):184\u201389. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.04.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"7469_CR11","first-page":"106","volume":"125","author":"N Iniesta Arandia","year":"2020","unstructured":"Iniesta Arandia N, Espinosa G, Tolosa Vilella C, Del Castillo A G, Rubio Rivas M, Freire M, et al.; RESCLE Investigators, Autoimmune Diseases Study Group (GEAS). Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement. Clin Exp Rheumatol. 2020 May-Jun; 38 Suppl 125(3):106\u201314.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"7469_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s12016-022-08946-w","volume":"64","author":"I Cavazzana","year":"2022","unstructured":"Cavazzana I, Vojinovic T, Airo\u2019 P, Fredi M, Ceribelli A, Pedretti E, et al. Systemic sclerosis-specific antibodies: novel and classical biomarkers. Clin Rev Allergy Immunol. 2022, Jun, 18;64(3):412\u201330. https:\/\/doi.org\/10.1007\/s12016-022-08946-w.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2 Suppl 76","key":"7469_CR13","first-page":"96","volume":"31","author":"IAFM Heijnen","year":"2013","unstructured":"Heijnen IAFM, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V, et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol. 2013, Mar-Apr;31(2 Suppl 76):96\u2013102.","journal-title":"Clin Exp Rheumatol"},{"issue":"11","key":"7469_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"van den Hoogen F","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of Rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013, Nov;72(11):1747\u201355.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7469_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12016-021-08911-z","volume":"63","author":"EKL Chan","year":"2022","unstructured":"Chan EKL. Anti-Ro52 autoantibody is common in systemic autoimmune rheumatic diseases and correlates with worse outcome when associated with interstitial lung disease in systemic sclerosis and autoimmune myositis. Clin Rev Allergy Immunol. 2022, Oct;63(2):178\u201393. https:\/\/doi.org\/10.1007\/s12016-021-08911-z.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"7469_CR16","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/art.39755","volume":"68","author":"ZE Betteridge","year":"2016","unstructured":"Betteridge ZE, Woodhead F, Lu H, Shaddick G, Bunn CC, Denton CP, et al. Brief report: Anti-Eukaryotic initiation Factor 2B autoantibodies are associated with interstitial lung disease in patients with systemic sclerosis. Arthritis Rheumatol. 2016, Nov;68(11):2778\u201383. https:\/\/doi.org\/10.1002\/art.39755.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"7469_CR17","doi-asserted-by":"publisher","first-page":"102583","DOI":"10.1016\/j.autrev.2020.102583","volume":"19","author":"M Mahler","year":"2020","unstructured":"Mahler M, Hudson M, Bentow C, Roup F, Beretta L, Sime\u00f3n CP, et al. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmun Rev. 2020, Aug;19(8):102583. https:\/\/doi.org\/10.1016\/j.autrev.2020.102583.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"7469_CR18","doi-asserted-by":"publisher","first-page":"e004580","DOI":"10.1136\/rmdopen-2024-004580","volume":"10","author":"K Didier","year":"2024","unstructured":"Didier K, Sobanski V, Robbins A, Truchetet M-E, Barnetche T, Contin-Bordes C, et al. Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients. RMD Open. 2024, Nov, 20;10(4):e004580. https:\/\/doi.org\/10.1136\/rmdopen-2024-004580.","journal-title":"RMD Open"},{"key":"7469_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-3-030-92616-8_10","volume":"1367","author":"B \u00dcnl\u00fc","year":"2022","unstructured":"\u00dcnl\u00fc B, T\u00fcrsen U, Rajabi Z, Jabalameli N, Rajabi F. The immunogenetics of systemic sclerosis. Adv Exp Med Biol. 2022;1367:259\u201398. https:\/\/doi.org\/10.1007\/978-3-030-92616-8_10.","journal-title":"Adv Exp Med Biol"},{"key":"7469_CR20","doi-asserted-by":"publisher","first-page":"911977","DOI":"10.3389\/fmed.2022.911977","volume":"9","author":"M Noviani","year":"2022","unstructured":"Noviani M, Chellamuthu VR, Albani S, Low AHL. Toward molecular stratification and precision medicine in systemic sclerosis. Front Med (Lausanne). 2022, Jun, 30;9:911977. https:\/\/doi.org\/10.3389\/fmed.2022.911977.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"7469_CR21","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/acr.24998","volume":"75","author":"M Yang","year":"2023","unstructured":"Yang M, Goh V, Lee J, Espinoza M, Yuan Y, Carns M, et al. Clinical phenotypes of patients with systemic sclerosis with distinct molecular signatures in skin. Arthritis Care Res (hoboken). 2023, Jul;75(7):1469\u201380. https:\/\/doi.org\/10.1002\/acr.24998.","journal-title":"Arthritis Care Res (hoboken)"},{"issue":"6","key":"7469_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/BOR.0000000000000967","volume":"35","author":"X Bi","year":"2023","unstructured":"Bi X, Mills T, Wu M. Animal models in systemic sclerosis: an update. Curr Opin Rheumatol. 2023;35(6):364\u201370. https:\/\/doi.org\/10.1097\/BOR.0000000000000967.","journal-title":"Curr Opin Rheumatol"},{"key":"7469_CR23","unstructured":"Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud. Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases: (PRECISESADS). ClinicalTrials.gov. Identifier: NCT02890121. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02890121."},{"key":"7469_CR24","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot5439","volume-title":"Rna: a laboratory manual","author":"DC Rio","year":"2010","unstructured":"Rio DC, Ares MJ, Hannon GJ, Tw N. Protocol: purification of rna using TRIzol (tri reagent). In: Rna: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2010. https:\/\/doi.org\/10.1101\/pdb.prot5439."},{"issue":"2","key":"7469_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s11926-012-0304-0","volume":"15","author":"T Iwayama","year":"2013","unstructured":"Iwayama T, Olson LE. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities. Curr Rheumatol Rep. 2013;15(2):304. https:\/\/doi.org\/10.1007\/s11926-012-0304-0.","journal-title":"Curr Rheumatol Rep"},{"key":"7469_CR26","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1038\/s41467-021-24552-5","volume":"12","author":"D Sahoo","year":"2021","unstructured":"Sahoo D, Swanson L, Sayed IM, Katkar GD, Ibeawuchi S-R, Mittal Y, et al. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun. 2021;12:4246. https:\/\/doi.org\/10.1038\/s41467-021-24552-5.","journal-title":"Nat Commun"},{"key":"7469_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/bs.ai.2015.09.006","volume":"129","author":"H-C Chuang","year":"2016","unstructured":"Chuang H-C, Wang X, Tan T-H. MAP4K family kinases in immunity and inflammation. Adv Immunol. 2016;129:277\u2013314. https:\/\/doi.org\/10.1016\/bs.ai.2015.09.006.","journal-title":"Adv Immunol"},{"issue":"2","key":"7469_CR28","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/antiox10020256","volume":"10","author":"G Manco","year":"2021","unstructured":"Manco G, Porzio E, Carusone TM. Human paraoxonase-2 (PON2): protein functions and modulation. Antioxid (basel). 2021;10(2):256. https:\/\/doi.org\/10.3390\/antiox10020256.","journal-title":"Antioxid (basel)"},{"issue":"4","key":"7469_CR29","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/HJH.0000000000003679","volume":"42","author":"R Ram\u00edrez-Carracedo","year":"2024","unstructured":"Ram\u00edrez-Carracedo R, Hern\u00e1ndez I, Moreno-G\u00f3mez-Toledano R, D\u00edez-Mata J, Tesoro L, Gonz\u00e1lez-Cucharero C, et al. NOS3 prevents MMP-9, and MMP-13 induced extracellular matrix proteolytic degradation through specific microRNA-targeted expression of extracellular matrix metalloproteinase inducer in hypertension-related atherosclerosis. J Hypertens. 2024;42(4):685\u201393. https:\/\/doi.org\/10.1097\/HJH.0000000000003679.","journal-title":"J Hypertens"},{"issue":"4","key":"7469_CR30","doi-asserted-by":"publisher","first-page":"112327","DOI":"10.1016\/j.celrep.2023.112327","volume":"42","author":"W Ji","year":"2023","unstructured":"Ji W, Zhang L, Ma C, Xu X, Li S, Xia H, et al. Newly synthesized AIFM1 determines the hypersensitivity of T lymphocytes to sting activation-induced cell apoptosis. Cell Rep. 2023;42(4):112327. https:\/\/doi.org\/10.1016\/j.celrep.2023.112327.","journal-title":"Cell Rep"},{"key":"7469_CR31","doi-asserted-by":"publisher","first-page":"890121","DOI":"10.3389\/fcell.2022.890121","volume":"10","author":"J Zhu","year":"2022","unstructured":"Zhu J, Chu F, Zhang M, Sun W, Zhou F, et al. Association between neddylation and immune response. Front. Cell Dev. Biol. 2022;10:890121. https:\/\/doi.org\/10.3389\/fcell.2022.890121.","journal-title":"Front. Cell Dev. Biol"},{"issue":"6","key":"7469_CR32","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/art.41192","volume":"72","author":"M Liang","year":"2020","unstructured":"Liang M, Lv J, Jiang Z, He H, Chen C, Xiong Y, et al. Promotion of myofibroblast differentiation and tissue fibrosis by the leukotriene B4\u2013leukotriene B4 receptor axis in systemic sclerosis. Arthritis Rheumatol. 2020;72(6):1013\u201325. https:\/\/doi.org\/10.1002\/art.41192.","journal-title":"Arthritis Rheumatol"},{"key":"7469_CR33","doi-asserted-by":"publisher","first-page":"1382371","DOI":"10.3389\/fgene.2024.1382371","volume":"15","author":"D Prawitt","year":"2024","unstructured":"Prawitt D, Eggermann T. Molecular mechanisms of human overgrowth and use of omics in its diagnostics: chances and challenges. Front Genet. 2024;15:1382371. https:\/\/doi.org\/10.3389\/fgene.2024.1382371.","journal-title":"Front Genet"},{"issue":"18","key":"7469_CR34","doi-asserted-by":"publisher","first-page":"e2206606","DOI":"10.1002\/advs.202206606","volume":"10","author":"L Gao","year":"2023","unstructured":"Gao L, Sun Y, Zhang X, Ma D, Xie A, Wang E, et al. Wnt3a-loaded extracellular vesicles promote alveolar epithelial regeneration after lung injury. Adv Sci (Weinh). 2023;10(18):e2206606. https:\/\/doi.org\/10.1002\/advs.202206606.","journal-title":"Adv Sci (Weinh)"},{"key":"7469_CR35","doi-asserted-by":"publisher","first-page":"653950","DOI":"10.3389\/fimmu.2021.653950","volume":"12","author":"G De Luca","year":"2021","unstructured":"De Luca G, Cavalli G, Campochiaro C, Bruni C, Tomelleri A, Dagna L, et al. Interleukin-1 and systemic sclerosis: getting to the heart of cardiac involvement. Front Immunol. 2021;12:653950. https:\/\/doi.org\/10.3389\/fimmu.2021.653950.","journal-title":"Front Immunol"},{"issue":"4 Suppl","key":"7469_CR36","doi-asserted-by":"publisher","first-page":"A6497","DOI":"10.1016\/j.chest.2024.07.098","volume":"166","author":"O Koneva","year":"2024","unstructured":"Koneva O, Shayakhmetova R, Garzanova L, Ovsyannikova O, Desinova O, Starovoytova M, et al. TNF-alfa in systemic sclerosis: clinical and laboratory association. Chest. 2024;166(4 Suppl):A6497.","journal-title":"Chest"},{"key":"7469_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, Jj O, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345. https:\/\/doi.org\/10.1038\/s41584-021-00726-8.","journal-title":"Nat Rev Rheumatol"},{"key":"7469_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202205231","author":"LK Thoidingjam","year":"2022","unstructured":"Thoidingjam LK, Blouin CM, Gaillet C, Brion A, Solier S, Niyomchon S, et al. Small molecule inhibitors of interferon-induced JAK-STAT signalling. Angew Chem Int Ed Engl. 2022. https:\/\/doi.org\/10.1002\/anie.202205231.","journal-title":"Angew Chem Int Ed Engl"},{"key":"7469_CR39","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","volume":"178","author":"A Lescoat","year":"2020","unstructured":"Lescoat A, Lelong M, Jeljeli M, Piquet-Pellorce C, Morzadec C, Ballerie A, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochem Pharmacol. 2020;178:114103. https:\/\/doi.org\/10.1016\/j.bcp.2020.114103.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"7469_CR40","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/life12122101","volume":"12","author":"E Fiorentini","year":"2022","unstructured":"Fiorentini E, Bonomi F, Peretti S, Orlandi M, Lepri G, Matucci Cerinic M. Potential role of jak inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: a narrative review from pathogenesis to real-life data. Life (Basel). 2022;12(12):2101. https:\/\/doi.org\/10.3390\/life12122101.","journal-title":"Life (Basel)"},{"issue":"6","key":"7469_CR41","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","volume":"34","author":"V Kakkar","year":"2022","unstructured":"Kakkar V, Assassi S, Allanore Y, Kuwana M, Denton CP, Khanna D, et al. Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Curr Opin Rheumatol. 2022, Sep, 16;34(6):357\u201364. https:\/\/doi.org\/10.1097\/BOR.0000000000000907.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"7469_CR42","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/art.43029","volume":"77","author":"J Bryon","year":"2025","unstructured":"Bryon J, Wasson CW, Koeppen K, Chandler F, Willis LF, Di Donato S, et al. Systemic sclerosis dermal fibroblast exosomes trigger type 1 interferon responses in keratinocytes via a TBK\/JAK\/STAT signaling axis. Arthritis Rheumatol. 2025;77(3):322\u201334. https:\/\/doi.org\/10.1002\/art.43029.","journal-title":"Arthritis Rheumatol"},{"key":"7469_CR43","unstructured":"Maillet F, Schmidt C, Bondet V, Bense A, Duffy D, Mouthon L, et al. High levels of circulating IFN\u03b1 are associated with increased mortality in patients with diffuse cutaneous systemic sclerosis [abstract]. Arthritis Rheumatol. 2024;76(Suppl 9). Available from: https:\/\/acrabstracts.org\/abstract\/high-levels-of-circulating-ifn%ce%b1-are-associated-with-increased-mortality-in-patients-with-diffuse-cutaneous-systemic-sclerosis\/."},{"issue":"10","key":"7469_CR44","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/jid.2015.188","volume":"135","author":"X Guo","year":"2015","unstructured":"Guo X, Higgs BW, Bay-Jensen AC, Karsdal MA, Yao Y, Roskos LK, et al. Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis. The J Invest Dermatol. 2015, Oct;135(10):2402\u201309. https:\/\/doi.org\/10.1038\/jid.2015.188.","journal-title":"The J Invest Dermatol"},{"issue":"8","key":"7469_CR45","first-page":"1635","volume":"42","author":"D Khanna","year":"2024","unstructured":"Khanna D, Denton CP, Assassi S, Kuwana M, Allanore Y, Domsic RT, et al. A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to determine the effectiveness of the type I interferon receptor antibody, anifrolumab, in systemic sclerosis: daisy study design and rationale. Clin Exp Rheumatol. 2024, Aug;42(8):1635\u201344.","journal-title":"Clin Exp Rheumatol"},{"key":"7469_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopha.2018.07.155","volume":"107","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wang Y, Wang L, Yin G, Li W, Xian Y, et al. miR-23c suppresses tumor growth of human hepatocellular carcinoma by attenuating ERBB2IP. Biomed Pharmacother. 2018;107:424\u201332. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.155.","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"7469_CR47","doi-asserted-by":"publisher","first-page":"11212","DOI":"10.3390\/ijms241311212","volume":"24","author":"V Spasovski","year":"2023","unstructured":"Spasovski V, Andjelkovic M, Parezanovic M, Komazec J, Ugrin M, Klaassen K, et al. The role of autophagy and apoptosis in affected skin and lungs in patients with systemic sclerosis. Int J Mol Sci. 2023;24(13):11212. https:\/\/doi.org\/10.3390\/ijms241311212.","journal-title":"Int J Mol Sci"},{"key":"7469_CR48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrrheum.2018.5","volume":"14","author":"J Collison","year":"2018","unstructured":"Collison J. Promoting apoptosis is key to reversing fibrosis. Nat Rev Rheumatol. 2018;14:61. https:\/\/doi.org\/10.1038\/nrrheum.2018.5.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"7469_CR49","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/art.40906","volume":"71","author":"V Sobanski","year":"2019","unstructured":"Sobanski V, Giovannelli J, Allanore Y, Riemekasten G, Air\u00f2 P, Vettori S, et al. Phenotypes determined by cluster analysis and their survival in the prospective European Scleroderma trials and research cohort of patients with systemic sclerosis. Arthritis Rheumatol. 2019;71(9):1553\u201370. https:\/\/doi.org\/10.1002\/art.40906.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"7469_CR50","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(22)00122-3","volume":"4","author":"KEN Clark","year":"2022","unstructured":"Clark KEN, Csomor E, Campochiaro C, Galwey N, Nevin K, Morse MA, et al. Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study. Lancet Rheumatol. 2022;4(7):e507\u201316. https:\/\/doi.org\/10.1016\/S2665-9913(22)00122-3.","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"7469_CR51","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1136\/ard-2022-223986","volume":"82","author":"KEN Clark","year":"2023","unstructured":"Clark KEN, Xu S, Attah M, Ong VH, Buckley CD, Denton CP. Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups. Ann Rheum Dis. 2023;82(12):1513\u201322. https:\/\/doi.org\/10.1136\/ard-2022-223986.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7469_CR52","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1093\/rheumatology\/keac492","volume":"62","author":"C Bellocchi","year":"2023","unstructured":"Bellocchi C, Beretta L, Wang X, Lyons MA, Marchini M, Lorini M, et al. Longitudinal global transcriptomic profiling of preclinical systemic sclerosis reveals molecular changes associated with disease progression. Rheumatol (oxford). 2023;62(4):1662\u201368. https:\/\/doi.org\/10.1093\/rheumatology\/keac492.","journal-title":"Rheumatol (oxford)"},{"issue":"4","key":"7469_CR53","first-page":"21","volume":"106","author":"PJ Wermuth","year":"2017","unstructured":"Wermuth PJ, Piera-Velazquez S, Jimenez SA. Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts. Clin Exp Rheumatol. 2017;35 Suppl 106(4):21\u201330.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"7469_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.22038\/ijogi.2024.70879.5639","volume":"27","author":"SS Bahreiny","year":"2024","unstructured":"Bahreiny SS, Ahangarpour A, Hoseinynejad K, Bitaraf S, Dabbagh MR, Aghli Moghadam M, et al. Association of KCNJ11 (rs5219) gene polymorphism with susceptibility to gestational diabetes mellitus: a review and meta-analysis. Iran J Obstet Gynecol Infertil. 2024;27(1):63\u201379. https:\/\/doi.org\/10.22038\/ijogi.2024.70879.5639.","journal-title":"Iran J Obstet Gynecol Infertil"},{"key":"7469_CR55","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.clnesp.2024.07.015","volume":"63","author":"R Mohammadpour Fard","year":"2024","unstructured":"Mohammadpour Fard R, Rashno M, Bahreiny SS. Effects of melatonin supplementation on markers of inflammation and oxidative stress in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2024;63:530\u201339.","journal-title":"Clin Nutr ESPEN"},{"key":"7469_CR56","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40200-024-01461-z","volume":"23","author":"SS Bahreiny","year":"2024","unstructured":"Bahreiny SS, Ahangarpour A, Aghaei M, et al. A closer look at galectin-3: its association with gestational diabetes mellitus revealed by systematic review and meta-analysis. J Diabetes Metab Disord. 2024;23:1621\u201333. https:\/\/doi.org\/10.1007\/s40200-024-01461-z.","journal-title":"J Diabetes Metab Disord"},{"key":"7469_CR57","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s13098-025-01849-8","volume":"17","author":"R Mohammadpour Fard","year":"2025","unstructured":"Mohammadpour Fard R, Sherafat NS, Rashno M, et al. Evaluating pentraxin 3 as a diagnostic biomarker for diabetic retinopathy: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025;17:273. https:\/\/doi.org\/10.1186\/s13098-025-01849-8.","journal-title":"Diabetol Metab Syndr"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07469-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07469-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:07:21Z","timestamp":1767478041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07469-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7469"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07469-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7109703\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"12 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. All participants received full information about the study and provided written informed consent prior to inclusion. The PRECISESADS protocol is registered at ClinicalTrials.gov (NCT02890121). Local approvals were obtained from the research ethics committees of all participating centers, including Reina Sof\u00eda University Hospital (approval no. 5995).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript does not contain individual person\u2019s data (images, videos, or details) requiring specific consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI, San Francisco, CA) in order to assist with language editing, style refinement, and structural suggestions for improved clarity and readability. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"17"}}